Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state

Pharmaceutical Research

Volumn 24, Issue 10, 2007, Pages 1862-1869

  Brouwers, Joachim ^a   Tack, Jan ^b   Augustijns, Patrick ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

(Fos)amprenavir; Food effect; Intraluminal drug behavior; Pharmacokinetics; Tablet disintegration

Indexed keywords

AMPRENAVIR; AMPRENAVIR PHOSPHATE; PHOSPHATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DEPHOSPHORYLATION; DIET RESTRICTION; DIETARY INTAKE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG RESEARCH; DRUG SOLUBILITY; FEMALE; FOOD; FOOD DRUG INTERACTION; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; INTESTINE ABSORPTION; INTESTINE FLUID; MALE; PH; PRIORITY JOURNAL; STOMACH JUICE; TABLET DISINTEGRATION;

ADMINISTRATION, ORAL; ADULT; CARBAMATES; CROSS-OVER STUDIES; DUODENUM; FASTING; FEASIBILITY STUDIES; FEMALE; FOOD-DRUG INTERACTIONS; GASTRIC JUICE; HIV PROTEASE INHIBITORS; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; INTESTINAL SECRETIONS; MALE; PHOSPHORIC ACID ESTERS; POSTPRANDIAL PERIOD; SOLUBILITY; SULFONAMIDES; TABLETS;

EID: 34548082187     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9307-3     Document Type: Article

References (17)

1. I. R. Wilding, A. J. Coupe, and S. S. Davis. The role of gamma-scintigraphy in oral drug delivery. Adv. Drug Deliv. Rev. 46:103-124 (2001).
2. W. Weitschies, O. Kosch, H. Monnikes, and L. Trahms. Magnetic marker monitoring: An application of biomagnetic measurement instrumentation and principles for the determination of the gastrointestinal behavior of magnetically marked solid dosage forms. Adv. Drug Deliv. Rev. 57:1210-1222 (2005).
3. L. Bonlokke, L. Hovgaard, H. G. Kristensen, L. Knutson, and H. Lennernas. Direct estimation of the in vivo dissolution of spironolactone, in two particle size ranges, using the single-pass perfusion technique (Loc-I-Gut) in humans. Eur. J. Pharm. Sci. 12:239-250 (2001).
4. N. Petri, C. Tannergren, B. Holst, F. A. Mellon, Y. Bao, G. W. Plumb, J. Bacon, K. A. O'Leary, P. A. Kroon, L. Knutson, P. Forsell, T. Eriksson, H. Lennernas, and G. Williamson. Absorption/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo. Drug Metab. Dispos. 31:805-813 (2003).
5. C. Tannergren, T. Knutson, L. Knutson, and H. Lennernas. The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. Br. J. Clin. Pharmacol. 55:182-190 (2003).
6. E. Bergman, P. Forsell, A. Tevell, E. M. Persson, M. Hedeland, U. Bondesson, L. Knutson, and H. Lennernas. Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. Eur. J. Pharm. Sci. 29:205-214 (2006).
7. J. Brouwers, F. Ingels, J. Tack, and P. Augustijns. Determination of intraluminal theophylline concentrations after oral intake of an immediate- and a slow-release dosage form. J. Pharm. Pharmacol. 57:987-996 (2005).
8. J. Brouwers, J. Tack, F. Lammert, and P. Augustijns. Intraluminal drug and formulation behavior and integration in in vitro permeability estimation: a case study with amprenavir. J. Pharm. Sci. 95:372-383 (2006).
9. E. S. Furfine, C. T. Baker, M. R. Hale, D. J. Reynolds, J. A. Salisbury, A. D. Searle, S. D. Studenberg, D. Todd, R. D. Tung, and A. Spaltenstein. Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob. Agents Chemother. 48:791-798 (2004).
10. C. Falcoz, J. M. Jenkins, C. Bye, T. C. Hardman, K. B. Kenney, S. Studenberg, H. Fuder, and W. T. Prince. Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. J. Clin. Pharmacol. 42:887-898 (2002).
11. M. B. Wire, M. J. Shelton, and S. Studenberg. Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin. Pharmacokinet. 45:137-168 (2006).
12. J. Brouwers, J. Tack, and P. Augustijns. In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: Illustration of intraluminal supersaturation. Int. J. Pharm. (2007, in press). DOI: 10.1016/j.ijpharm.2006.12.011.
13. S. A. Müller-Lissner, C. J. Fimmel, N. Will, W. Müller-Duysing, F. Heinzel, and A. L. Blum. Effect of gastric and transpyloric tubes on gastric emptying and duodenogastric reflux. Gastroenterology 83:1276-1279 (1982).
14. W. Weitschies, R. Wedemeyer, O. Kosch, K. Fach, S. Nagel, E. Soderlind, L. Trahms, B. Abrahamsson, and H. Monnikes. Impact of the intragastric location of extended release tablets on food interactions. J. Control. Release 108:375-385 (2005).
15. J. M. Treluyer, G. Bowers, N. Cazali, M. Sonnier, E. Rey, G. Pons, and T. Cresteil. Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation. Drug Metab. Dispos. 31:275-281 (2003).
16. S. L. Ford, M. B. Wire, Y. Lou, K. L. Baker, and D. S. Stein. Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. Antimicrob. Agents Chemother. 49:467-469 (2005).
17. B. Abrahamsson, T. Albery, A. Eriksson, I. Gustafsson, and M. Sjoberg. Food effects on tablet disintegration. Eur. J. Pharm. Sci. 22:165-172 (2004).